Encouraging shifts in drug delivery to improve patient outcomes and reduce costs is an emerging UM focus area. One such strategy involves transitioning eligible injectable medications from Medicare Part B (typically IV/IM infusions in clinics) to Part D (self-administered subcutaneous injections at home). By empowering patients to self-administer when appropriate, providers can enhance convenience, treatment satisfaction and potentially lower total medical spending.

AAVBC’s Quick Reference Guide integrates the current clinical evidence and CMS-aligned guideline standards into a concise understanding of a successful Part B-to-D drug transition program in a VBC framework. The guide provides clinicians and health providers with evidence-based direction on how to make self-injection feasible within the parameters of Medicare’s coverage rules without sacrificing efficacy – it outlines the clinical rationale, regulatory landscape as well as operational tactics.

AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of the Part B-to-D drug delivery initiative — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratification, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools, to support a deeper understanding of the Part B-to-D drug delivery initiative and provide multidisciplinary teams with strategies to thrive within value-based frameworks.